Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06395870 | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | PHASE1 | RECRUITING | 33 | — | — | May 9, 2024 | Jun 30, 2028 | Nov 6, 2024 | 2 | China |
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
CAR positive T cells and CAR transgene levels in peripheral blood after LUCAR-G39D infusion.
CAR positive T cells and CAR transgene levels in bone marrow after LUCAR-G39D infusion.
RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion.
| Arm | Type | Description |
|---|---|---|
| LUCAR-G39D cells product | EXPERIMENTAL | Each subject will be given a single-dose LUCAR-G39D cells infusion at each dose level. |
| Name | Type | Description |
|---|---|---|
| LUCAR-G39D cells product | BIOLOGICAL | Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine. |
Inclusion Criteria: 1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent. 2. Aged 18-75 years (inclusive). 3. Eastern Cooperative Oncology Group (ECOG) perf...